Q1 2025 Pharming Group NV Earnings Call Transcript

May 8, 2025 / 11:30 AM GMT

Release Date Price: $10.01 (+11.22%)

Transcript

Key Points

Positve

Pharming Group (PHGUF) reported a 42% increase in total revenues for Q1 2025, driven by strong sales of Ruconest and Joenja.
Ruconest sales grew by 49% to $68.6 million, supported by increased patient enrollment and an expanded prescriber base.
The company has initiated phase 2 studies for genetic PID and CID, which could significantly expand the addressable patient population.
Pharming Group (PHGUF) has successfully reduced its operating loss and generated a profit for the third consecutive quarter, excluding non-recurring expenses.
The company has raised its full-year revenue guidance, reflecting confidence in continued growth and financial discipline.

Negative

Operating expenses increased due to non-recurring Aliva acquisition-related costs of $7.8 million.
The net loss for Q1 2025 was $14.9 million, primarily due to non-tax deductible acquisition expenses and foreign exchange exposure.
Cash and marketable securities decreased by $60.5 million, largely due to the Aliva acquisition.
Potential import tariffs between the US and Europe could impact Pharming Group (PHGUF)'s supply chain and pricing strategies.
The company faces challenges in reducing general and administrative expenses by $10 million annually while maintaining growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAR.AS - Pharming Group NV
Q1 2025 Pharming Group NV Earnings Call
May 08, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the Farming 1st quarter 2025 results conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a telephone question, please press 11 on your keypad to join the queue. To withdraw your question, press 11 again.

Please be advised that today's conference is being recorded. I would now like to hand over to Fabrice Shuai, who's CEO. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Hello, everyone and welcome to this Q1

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.